OncoMed Pharmaceuticals completes enrollment of phase 2 PINNACLE clinical trial
OncoMed announced completion of patient enrollment in the Phase 2 "PINNACLE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for treatment of small cell lung cancer. The PINNACLE study enrolled 145 patients with extensive-stage SCLC who had not received prior treatment. August 30, 2016